Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome
Mol Ther. 2024 May 24:S1525-0016(24)00336-8. doi: 10.1016/j.ymthe.2024.05.034. Online ahead of print. ABSTRACT Prader-Willi syndrome (PWS) is the prototypic genomic disorder resulting from deficiency of paternally …